Last reviewed · How we verify
CD1579 5%
CD1579 5% is a topical retinoid that modulates cell growth and differentiation.
CD1579 5% is a topical retinoid that modulates cell growth and differentiation. Used for Acne vulgaris, Photoaging.
At a glance
| Generic name | CD1579 5% |
|---|---|
| Also known as | Benzoyl Peroxide 5% |
| Sponsor | Galderma R&D |
| Drug class | retinoid |
| Target | retinoic acid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
CD1579 5% works by binding to retinoic acid receptors, which are involved in regulating cell growth and differentiation. This leads to an increase in cell turnover and a decrease in the appearance of fine lines and wrinkles.
Approved indications
- Acne vulgaris
- Photoaging
Common side effects
- Skin irritation
- Dryness
- Redness
Key clinical trials
- Efficacy and Safety of CD5024 1% in Acne Vulgaris (PHASE2)
- A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients (PHASE1)
- Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD1579 5% CI brief — competitive landscape report
- CD1579 5% updates RSS · CI watch RSS
- Galderma R&D portfolio CI